Island Pharmaceuticals Ltd · ASX:ILA
Island Pharmaceuticals — 9th Asia Dengue Summit (June 2026)
16 slides from Island Pharmaceuticals's conference presentation, Jun 16, 2026
Slide 1: Investor Presentation - Asia Dengue Summit (ASX Announcement)
16 June 2026 ASX Announcement Investor Presentation - Asia Dengue Summit MELBOURNE Australia, 16 June 2026: Australian antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA; Island or the Company) advises that Dr. David Foster CEO and Managing Director of Island is presenting new
Slide 2: Combatting Urgent Viral Disease Threats
COMBATTING URGENT VIRAL DISEASE THREATS Asia Dengue Summit Dr David Foster, CEO & Managing Director June 2026 ASX: ILA
Slide 3: Island Pharmaceuticals (ASX: ILA)
Island Pharmaceuticals (ASX: ILA) Two programs targeting infectious diseases Phase 2a PROTECT clinical trial in dengue Two, well advanced clinical stage programs complete with ISLA-101 Major market potential via both programs Positive FDA feedback on Animal Rule regulatory path for galidesivir Multi
Slide 4: ISLA-101 – Broad Activity Evident
ISLA-101 – BROAD ACTIVITY EVIDENT 1 DENGUE 1-4 • ISLA-101 has demonstrated broad anti-viral activity in in- vitro models 2 ZIKA • Demonstrated potent anti dengue-1 activity in in-vitro models using fresh human cells • Protective in dengue fever and Zika in animal models 3 WEST NILE • Shown to preven
Slide 5: Preventing Animal Deaths from Lethal Dengue and Protective Against Zika
PREVENTING ANIMAL DEATHS FROM LETHAL DENGUE AND PROTECTIVE AGAINST ZIKA Two daily doses of Isla101 prevent 70% of deaths by otherwise lethal dengue Survival curve showing protection from lethal dengue change by Increasing dose of ISLA101 (mouse model). Fraser et al. 2014 Island Pharmaceuticals Limit
Slide 6: Phase 2A (PROTECT) Proof of Concept
PHASE 2A (PROTECT) PROOF OF CONCEPT Phase 2A: Prophylactic (preventative) cohort • Single dose proof of concept study in a dengue human infection model at SUNY Upstate • Phase 2a (prophylactic) subjects dosed initially (3 active: 1 placebo) • Safety Review Committee review highlighted: ⚬ Administeri
Slide 7: Pharmacokinetics of ISLA-101 in Treated Participants
PHARMACOKINETICS OF ISLA-101 IN TREATED PARTICIPANTS Plasma concentration–time profiles of ISLA-101 across dosing in study participants. Island Pharmaceuticals Limited 06
Slide 8: Virologic Characteristics of ISLA-101 Treated Subjects - RNAemia
VIROLOGIC CHARACTERISTICS OF ISLA-101 TREATED SUBJECTS- RNAEMIA dy tu ls ro nt Co Plasma concentration–time profiles of ISLA-101 across dosing in study participants. Island Pharmaceuticals Limited 07
Slide 9: Virologic Characteristics of ISLA-101 Treated Subjects - Viremia
VIROLOGIC CHARACTERISTICS OF ISLA-101 TREATED SUBJECTS- VIREMIA Plasma concentration–time profiles of ISLA-101 across dosing in study participants. Island Pharmaceuticals Limited 08
Slide 10: Virologic Characteristics of ISLA-101 Treated Subjects - NS1
VIROLOGIC CHARACTERISTICS OF ISLA-101 TREATED SUBJECTS- NS1 Plasma concentration–time profiles of ISLA-101 across dosing in study participants. Island Pharmaceuticals Limited 09
Slide 11: Spearman Correlation of Peak RNAemia or Viremia and Day of RNAemia Onset
Spearman Correlation of Peak RNAemia or Viremia and day of RNAemia onset in Treatment Cohort Controls (placebo and control study) Controls (placebo and control study) Island Pharmaceuticals Limited 10
Slide 12: Earlier ISLA-101 Treatment Leads to Lower Cumulative Viremia
Earlier ISLA-101 Treatment Leads to Lower Cumulative Viremia Island Pharmaceuticals Limited 11
Slide 13: Summary of Signs & Symptoms
SUMMARY OF SIGNS & SYMPTOMS Island Pharmaceuticals Limited 12
Slide 14: Positive Phase 2 Top-Line Results
POSITIVE PHASE 2 TOP-LINE RESULTS: • Achieved desired plasma concentration of ISLA-101 • Positive top-line results advocate for ongoing clinical development of ISLA-101 in dengue • ISLA-101 delivered meaningful reduction in viremia (viral load) and symptoms in preventative cohort • Treatment cohort
Slide 15: Clinical Trial and Regulatory Pathway
CLINICAL TRIAL AND REGULATORY PATHWAY A defined clinical and regulatory route based on Phase 2a/b study results • Two likely pathways depending on Phase 2a/b results • Discussions advancing with multiple potential strategic partners for additional phase 2 and 3 clinical trials Phase 2b Phase 3 treat
Slide 16: Island Pharmaceuticals
Island Pharmaceuticals ASX: ILA dfoster@islandpharmaceuticals.com islandpharmaceuticals.com @IslandPharma Island Pharmaceuticals
Island Pharmaceuticals — 9th Asia Dengue Summit (June 2026) on 6ix